Cantargia AB (FRA:7V3) Interest Income : €0.82 Mil (TTM As of Dec. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Cantargia AB Interest Income?

Interest Income is the interest earned on cash temporarily held in savings accounts, certificates of deposits, or other investments. Cantargia AB's interest income for the three months ended in Dec. 2024 was €0.17 Mil. Its interest income for the trailing twelve months (TTM) ended in Dec. 2024 was €0.82 Mil.

Cantargia AB Interest Income Historical Data

The historical data trend for Cantargia AB's Interest Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cantargia AB Interest Income Chart

Cantargia AB Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Interest Income

Get a 7-Day Free Trial

0.05

0.09

0.04

0.38

0.42

Cantargia AB Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Interest Income	Get a 7-Day Free Trial															0.43	0.44	0.05	0.17	0.17

Cantargia AB Interest Income Calculation

Interest Income is the interest earned on cash temporarily held in savings accounts, certificates of deposits, or other investments.

Interest Income for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.82 Mil.

Cantargia AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cantargia AB (FRA:7V3) » Definitions » Interest Income

Comparable Companies

Traded in Other Exchanges

CANTA:Sweden

Address

Scheelevagen 27, Lund, SWE, SE-223 63

Website

https://www.cantargia.com

Cantargia AB is engaged in the development of products used in the treatment of cancer. It has developed specific antibodies against IL1RAP to treat serious, life-threatening diseases. The company's first product candidate, CAN04, has also been designed to treat different forms of cancer, with the initial focus on the treatment of non-small cell lung cancer and pancreatic cancer. The CAN10 project covers a disease segment that complements nadunolimab and diversifies Cantargia's project portfolio.

Cantargia AB Headlines

No Headlines